{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.9","value":"14.4"},{"groupId":"OG001","spread":"3.4","value":"13.5"},{"groupId":"OG002","spread":"2.9","value":"14.2"},{"groupId":"OG003","spread":"3.5","value":"14.1"}]}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.2","value":"14.1"},{"groupId":"OG001","spread":"3.6","value":"13.3"},{"groupId":"OG002","spread":"3.5","value":"13.7"},{"groupId":"OG003","spread":"3.2","value":"14.2"}]}],"title":"Pre-cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.5","value":"13.1"},{"groupId":"OG001","spread":"3.7","value":"13.1"},{"groupId":"OG002","spread":"3.0","value":"14.1"},{"groupId":"OG003","spread":"3.2","value":"14.4"}]}],"title":"Pre-cycle 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.2","value":"11.1"},{"groupId":"OG001","spread":"4.7","value":"11.4"},{"groupId":"OG002","spread":"3.7","value":"12.3"},{"groupId":"OG003","spread":"3.5","value":"13.1"}]}],"title":"9 months post cycle 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"89"},{"groupId":"OG002","value":"91"},{"groupId":"OG003","value":"96"}],"units":"Participants"}],"description":"The FACT/GOG-Ntx subscale contains 4 items. Each item was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). For the negative items, reversal was performed prior to score calculation. According to the FACIT measurement system, the Ntx score was the summation of the individual item scores if more than 50% of subscale items were answered. When unanswered items existed, a subscale score was prorated by multiplying the mean of the answered item scores by the number of items in the scale. The Ntx score ranges 0-16 with a large score suggests less neurotoxicity.","dispersionType":"Standard Deviation","groups":[{"description":"Patients receive paclitaxel IV over 24 hours on day 1 and cisplatin IV over 1-4 hours on day 2.\n\nCisplatin: Given IV\n\nPaclitaxel: Given IV\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG000","title":"Arm I (Paclitaxel, Cisplatin)"},{"description":"Patients receive vinorelbine IV over 6-10 minutes on days 1 and 8 and cisplatin IV over 1-4 hours on day 1.\n\nCisplatin: Given IV\n\nQuality-of-Life Assessment: Ancillary studies\n\nVinorelbine Tartrate: Given IV","id":"OG001","title":"Arm II (Vinorelbine, Cisplatin)"},{"description":"Patients receive gemcitabine IV over 30-60 minutes on days 1 and 8 and cisplatin as in arm II.\n\nCisplatin: Given IV\n\nGemcitabine Hydrochloride\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG002","title":"Arm III (Gemcitabine, Cisplatin)"},{"description":"Patients receive topotecan IV over 30 minutes on days 1-3 and cisplatin as in arm II.\n\nCisplatin: Given IV\n\nQuality-of-Life Assessment: Ancillary studies\n\nTopotecan Hydrochloride: Given IV","id":"OG003","title":"Arm IV (Topotecan, Cisplatin)"}],"paramType":"MEAN","populationDescription":"Patients who provided baseline and ≥ one follow-up assessments","reportingStatus":"POSTED","timeFrame":"Baseline (pre-cycle 1), Pre-cycle 2, Pre-cycle 5, 9 months post cycle 1","title":"Patient Reported Neurotoxicity Symptoms as Measured With the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity Subscale (Short Version) (FACT/GOG-Ntx Subscale).","type":"SECONDARY","unitOfMeasure":"units on a scale"}